Detail akcie Aprea Therapeut Rg online

Business Summary: Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aprea Therapeutics Inc revenues decreased 78% to $282K. Net loss increased 1% to $10.1M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment decrease of 69% to $282K. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 33% to $10.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.88 to -$1.65.